

Contents

Part I General ICU Topics

1 Evidence Based Critical Care	3
References.....	6
2 “Less Is More”: The New Paradigm in Critical Care	7
References.....	8
3 “Classic” Papers	13
4 Critical Care Medicine 101	19
Factors to Consider When a Patient is Admitted to the ICU.....	20
Initial “Generic” Treatment Orders.....	20
Reference	21
5 House Officers Guidelines 1: Housekeeping	23
Admission History and Physical Examination	23
Daily Examination	24
General.....	24
Vital Signs (24 h Min and Max and Current)	24
Additional Observations	24
The Ventilator.....	25
Heart.....	25
Chest	25
Abdomen.....	25
CNS.....	26
Importance of the Daily Neurological Examination.....	26
Laboratory Tests.....	26
Imaging	27
Presenting on Daily Rounds.....	27
New Admissions	27

Follow Up Patients 28

Clinical Pearls 28

References 28

6 House Officers Guidelines 2: Procedures 29

Murphy’s Laws of Procedures 29

Central Venous Access 30

 Subclavian Vein Catheterization 31

 Internal Jugular Vein Catheterization 32

 Femoral Vein Catheterization 33

 Complications of Central Venous Access 34

Arterial Catheters 34

Naso/Oro Gastric Tubes 35

Feeding Tubes 36

Thoracentesis and Paracentesis 36

 Clinical Pearls 37

References 37

7 Admission-Discharge Criteria 39

ICU Admission Criteria 39

Prioritization of Potential ICU Admissions 40

 Priority 1 40

 Priority 2 40

 Priority 3 40

 Priority 4 41

 Transfer from Another Hospital: Variable Priority 41

Disease Specific Indications for ICU Admission 41

 Cardiovascular System 41

 Pulmonary System 42

 Neurological Disorders 42

 Drug Ingestion and Drug Overdose 42

 Gastrointestinal Disorders 43

 Endocrine 43

 Renal Disorders 43

 Postoperative Care 44

 Miscellaneous 44

Physiologic Indication for ICU Admission 44

Discharge Criteria 44

Reference 45

**8 Chronic Critical Illness and the Long Term Sequela
of Critical Care 47**

Neuromuscular Abnormalities 49

 Critical Illness Polyneuropathy 49

 Critical Illness Myopathy (See also Chap. 32 on Nutrition) 49

 Brain Dysfunction 51

“Prevention” of CCI 51

Management of CCI.....	52
Testing.....	52
General Management.....	53
Stress Hyperglycemia.....	53
Metabolic Bone Disease.....	53
Anabolic Steroids.....	54
Exercise Program.....	54
References.....	54
9 Fluid Responsiveness and Fluid Resuscitation.....	57
Echocardiographic Assessment of Fluid Responsiveness.....	66
Static Echocardiographic Parameters.....	66
Dynamic Echocardiographic Parameters.....	66
Passive Leg Raising (PLR).....	67
The Fluid Challenge.....	69
Fluid Boluses in Volume Responsive Patients.....	71
What Type of Fluid?.....	72
Lactated Ringer’s (Hartmann’s Solution) vs. 0.9 % NaCl (Ab-Normal Saline).....	72
Complications Associated with 0.9 % NaCl vs. Lactate Ringers Solution.....	73
Renal Failure.....	73
Hyperchloremic Metabolic Acidosis and DEATH.....	73
Lactate Generates HCO ₃ ⁻	73
Ringer’s Lactate and Kidney Disease.....	74
Ringers Lactate and Liver Disease.....	75
Coagulopathy.....	75
Lactate as a Metabolic Fuel.....	75
Albumin.....	76
Hetastarches (HES).....	77
So, Which Fluid?.....	78
Resuscitation in Specific Disease States.....	78
Hemorrhage.....	78
Traumatic Brain Injury.....	79
Dehydration.....	79
Sepsis (and SIRS).....	80
Burns.....	80
Management of Oliguria.....	80
Management of Volume Overload/Acute Pulmonary Edema.....	81
References.....	81
10 Assessment of Cardiac Function and Cardiac Output.....	89
Echocardiographic Assessment of Cardiac Function.....	89
Methods of Measuring Cardiac Output.....	90
Pulmonary Artery Catheter.....	90
Transpulmonary Thermodilution.....	91

Pulse Contour Analysis	92
Esophageal Doppler	93
USCOM	93
Bioreactance.....	94
Utility of Cardiac Output monitoring	94
Determining Fluid and Inotrope Responsiveness	94
Driving up CI to Supranormal Values	94
References.....	95
11 Peri-operative Fluid Optimization	99
References.....	104
12 Sepsis	107
Bacteriology and Sites of Infection.....	108
Pathophysiology of Sepsis	109
Septic “Cardiomyopathy”	109
Complications Associated with Sepsis.....	111
Clinical Features and Diagnosis of Sepsis	112
Organ Dysfunction in Severe Sepsis/Septic Shock.....	112
Management of Sepsis	115
Antibiotic Therapy	118
Fluid Therapy (See also Chap. 9).....	119
Vasopressors and Inotropic Agents	124
B-Blockers and Phenylephrine in Septic Shock	128
Resuscitation End-Points	129
The Dangers of a HIGH CVP	130
Does Tissue Hypoxia and Mitochondrial Dysfunction Exist in Sepsis?	133
Case Example.....	136
References.....	137
13 The Stress Response, Stress Hyperglycemia and Stress Hyperlactemia.....	149
The Stress Response	149
Cardiovascular Effects of the Stress Response	152
Immune Effects of the Stress Response.....	152
Metabolic Effects of the Stress Response	153
Stress Hyperglycemia	153
Treatment of “Stress Hyperglycemia”	155
So What to Do!	157
How to Achieve These Goals?	157
Glucose Control and Steroids	158
Stress Hyperlactemia	158
Lactate Metabolism.....	159
Lactate as a Marker of Illness Severity	160
Lactate as a Marker of Metabolic Stress.....	161

Lactate as a Metabolic Fuel 162

Heart Metabolism and Lactate 163

Brain Metabolism and Lactate 163

References 164

14 Understanding the Vital Signs: BP, HR, RR, TEMP, SaO₂, ... and SV 169

Blood Pressure 169

 The Brain-Heart Distance and the Giraffe Theory of Blood Pressure Determination in Humans 170

 What's a Normal Blood Pressure? 171

 BP Thresholds for the Intensivist/Anesthesiologist 172

 Non-Invasive Blood Pressure (NIBP) vs Arterial Line Blood Pressure (IAP) and Systolic Blood Pressure (SBP) vs Mean Arterial Pressure (MAP)..... 172

 Central vs Peripheral Blood Pressure Measurement..... 173

 Blood Pressure Autoregulation 174

 MAP, Organ Failure and Death..... 175

Circulatory Shock 176

Pulse Rate..... 177

Respiratory Rate (& Pattern) 178

Temperature 179

Pulse Oximetry..... 179

Too Much Oxygen Kills..... 184

 Analysis of the Oximetric Waveform..... 188

Stroke Volume: The 6th Vital Sign..... 189

Putting the Vital Signs Together..... 190

 Early Warning Scoring Systems and Rapid Response Teams..... 191

References..... 192

15 Management of Pain, Agitation and Delirium 197

Assessing the Level of Pain and Sedation..... 200

 The Ramsey Sedation Scale 201

 The Richmond Agitation-Sedation Scale (RASS) 201

Sedation Vacations 202

Non-pharmacologic Interventions..... 202

Delirium 202

Sedative and Analgesics Agents..... 205

 Lorazepam..... 205

 Midazolam 206

 Propofol..... 206

 Dexmedetomidine 207

 Haloperidol 208

 Fentanyl..... 208

 Morphine..... 208

 Meperidine 208

Neuromuscular Blockade..... 209
 Neuromuscular Blocking Agents 209
 References..... 210

16 Hospital Acquired Infections and Their Prevention..... 213

Colonization with Multidrug Resistant Organisms..... 215
 Handwashing and Infection Control Measures..... 216
 Handwashing..... 216
 Chlorhexidine Bathing 216
 Gloves and Gowns and Healthcare Provider Apparel..... 217
 Universal Screening for MDR’s and “Protective Isolation” 217
 Oropharyngeal and Gastrointestinal Decolonization 218
 Private Rooms and Environmental Control 219
 Central Line Associated Blood Stream Infection..... 220
 Management of CLABSI’s 224
 Antibiotics Lock Therapy 225
 Prevention of CLABSI..... 225
 Catheter Associated Urinary Tract Infection..... 227
 Ventilator Associated Pneumonia 229
 Pathogenesis of VAP 230
 Diagnosis of VAP 232
 Treatment 234
 General Concepts for the Antimicrobial Treatment of VAP 234
 Empiric Antibiotic Choices..... 235
 “Specific” Interventions for Prevention of VAP..... 235
Clostridium difficile Infection 239
 Laboratory Diagnosis..... 241
 Sigmoidoscopy..... 242
 Treatment 243
 Fidaxomicin 244
 Adjunctive Treatment Options 244
 Probiotics 245
 Surgical Intervention..... 245
 Nosocomial Rhinosinusitis 246
 References..... 248

Part II Pulmonary

17 The Bacterial Pneumonias: A New Treatment Paradigm..... 261

Unified Treatment Algorithm..... 263
 No Risk Factors for a CAP-DRP 263
 Risk Factors for CAP-DRPs 264
 Influenza (Co-Existent or Influenza Pneumonia)..... 264
 Diagnostic Testing of Hospitalized Patients with Pneumonia 265
 Non-Infectious Diseases Masquerading as Pneumonia 265
 Special Considerations..... 266
 Severe CAP with no MDR Risk Factors..... 266

Community-Acquired MRSA Pneumonia (CA-MRSA).....	266
Aspiration Pneumonia.....	267
Nursing Home-Acquired Pneumonia.....	269
Persistent Temperature/Failure to Respond to Rx.....	269
Unusual Pathogens.....	270
Complicated Pleural Effusion/Empyema.....	271
References.....	271
18 Fever	275
Common Misconception and Fables.....	275
Pathogenesis of Fever.....	276
Treatment of Fever.....	276
Causes of Fever in the ICU.....	278
Infectious Causes of Fever in the ICU.....	279
Non-Infections Causes of Fever in the ICU.....	279
Non-Infectious Causes of Fever.....	279
An Approach to the Febrile ICU Patient.....	286
Clinical Pearls.....	288
References.....	288
19 Mechanical Ventilation 101	291
Alveolar Overdistension Damages Normal Lungs.....	293
Ventilator Variables and Modes of Ventilation.....	293
Ventilator Variables (See Table 19.1).....	297
Common Modes of Mechanical Ventilation.....	299
Positive End-Expiratory Pressure (PEEP).....	303
Auto-PEEP.....	305
Monitoring Patients Undergoing Mechanical Ventilation.....	306
Sudden Increase in Airway Pressure and/or Fall in Arterial Saturation.....	307
When to Perform a Tracheostomy.....	307
Timing of Tracheostomy in the Critically Ill.....	308
References.....	308
20 Non-invasive Ventilation	311
Set Up.....	312
Initial Settings.....	312
Indications of NIV.....	313
COPD Exacerbations.....	313
Acute Cardiogenic Pulmonary Edema.....	313
Facilitating Extubation in COPD Patients.....	313
Immunocompromised Patients.....	314
Post-operative Patients.....	314
When to Use NIV.....	315
Hypercapnic Respiratory Failure.....	315
Hypoxemic Respiratory Failure.....	315

- Contraindications to NIPPV 315
- Success and Failure Criteria for NIPPV 316
- References..... 316
- 21 Liberation (Weaning from Mechanical Ventilation)..... 319**
 - General Concepts 319
 - Effect of Liberation on Oxygen Consumption and Cardiac Function .. 320
 - Fluid Overload and Liberation Failure..... 320
 - Vasopressors and Inotropic Agents and Weaning 321
 - Mechanical Ventilation Liberation Process* 322
 - “Readiness” Testing 322
 - Spontaneous Breathing Trials 323
 - Causes of Liberation Failure 324
 - Early Extubation Followed by NIV in COPD 324
 - NIV for Persistent Liberation Failure 324
 - Extubation Failure..... 325
 - Patients at High Risk of Extubation Failure..... 325
 - The Cuff Leak Test..... 326
 - Corticosteroids for the Prevention of Post-extubation Stridor..... 326
 - References..... 326
- 22 Arterial Blood Gas Analysis..... 329**
 - Indications for ABG Sampling..... 329
 - ABG Sampling..... 330
 - ABG Analysis 331
 - Alveolar Ventilation 332
 - Oxygenation..... 332
 - Acid-Base Balance..... 334
 - A Step Wise Approach to Acid-Base Disorders..... 335
 - Common Acid Base Disturbances in the ICU..... 338
 - Metabolic Acidosis..... 338
 - Metabolic Alkalosis 341
 - Venous Blood Gas Analysis (VBGs) 342
 - Mixed Venous/Central Venous Oxygen Saturation 343
 - References..... 344
- 23 ARDS..... 349**
 - Definition, Causes and Assessment of Severity 349
 - Definition of ALI According the American European Consensus 349
 - Acute Lung Injury (ALI) 349
 - Acute Respiratory Distress Syndrome (ARDS)..... 350
 - Pathophysiological Definition of ARDS..... 350
 - Causes of ALI 351
 - Management of the Acute Phase of ARDS..... 351
 - Ventilatory Strategy 352
 - Pressure Controlled Ventilation..... 355

Airway Pressure Release Ventilation	357
Permissive Hypercapnia.....	359
Best PEEP	359
Recruitment Maneuvers	361
Non-Ventilatory Adjuncts to Gas Exchange	361
Prone Positioning	361
Neuromuscular Blocking Agents	362
ECMO	362
Corticosteroids	363
Inhaled Nitric Oxide	365
Nebulized Prostacyclin	365
β_2 -Adrenergic Receptor Agonists.....	365
Surfactant	365
Omega-3 Enteral Nutrition.....	366
“Our” Approach to Refractory Hypoxemia	366
References.....	367
24 COPD Exacerbation	373
Common Precipitating Events	374
Indications for Hospitalization.....	375
Indications for ICU Admission	375
Treatment	375
Indications for NPPV	377
Indications for Endotracheal Intubation.....	377
Mechanical Ventilation in COPD.....	377
Suggested Initial Settings.....	378
References.....	378
25 Acute Severe Asthma	381
Indications for Admission to the ICU	382
Initial Treatment.....	382
Other Therapeutic Options.....	383
Complications of Acute Asthma	384
Noninvasive Positive-Pressure Ventilation in Status Asthmaticus	384
Indications for Intubation.....	385
Sedation Post-intubation	386
Mechanical Ventilation.....	386
Initial Ventilator Settings.....	387
References.....	388
26 Pleural Effusions and Atelectasis	391
Pleural Effusions	391
Pathophysiology.....	391
Drainage of Pleural Effusion.....	392
Hepatic Hydrothorax.....	393

Alelectasis 393

 Respiratory Therapy 394

 Mucolytics..... 394

 Bronchoscopy 395

 Bilevel/APRV 395

References..... 396

27 Venous Thromboembolic Disease: DVT and PE 399

 Pregnancy, Venous Thromboembolism and Thrombophilias..... 399

 Site of Venous Thrombosis 400

 The Veins of the Lower Limb 401

 Suggested DVT Prophylaxis Protocols..... 405

 Diagnosis of DVT 405

 Distal Lower Extremity DVT..... 406

 Upper Extremity DVT 406

 Superficial Phlebitis 407

 Pulmonary Embolism..... 408

 Diagnosis of Pulmonary Embolism 408

 Treatment of Thromboembolic Disease..... 411

 Thrombolytic Therapy 413

 Catheter Directed Clot Fragmentation and Aspiration..... 418

 Inhaled Nitric Oxide 418

 Vena Caval Interruption 419

 “Absolute Contraindications” for Anticoagulation with Heparin 419

References..... 419

Part III Cardiac

28 Hypertensive Crises 429

 Definitions..... 429

 Pathophysiology 430

 Clinical Presentation 431

 Initial Evaluation..... 432

 Initial Management of Blood Pressure 433

 Resident (or Hospitalist) Called to the Floor for High Blood Pressure: What to Do?..... 434

 Drugs to AVOID..... 436

 Recommended Antihypertensive Agents 437

 Acute Postoperative Hypertension 439

 Pre-operative Hypertension..... 440

 Posterior Reversible Encephalopathy Syndrome (PRES)..... 441

 Pregnancy-Induced PRES 441

 Drugs Associated with PRES..... 442

References..... 442

29 Acute Decompensated Cardiac Failure..... 445

 Confirm the Diagnosis of Cardiac Failure 446

 Evaluation of the Patient with Cardiac Failure 447

 B-Type Natriuretic Peptides..... 447

 Echocardiography 448

 Laboratory Testing 448

 Hemodynamic Monitoring..... 448

 Precipitating Factors 449

 Treatment 449

 Acute Phase of Treatment 449

 Treatment of ADHF: Summary..... 456

 Long-Term Management 456

 Systolic Heart Failure 457

 Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)..... 461

 Takotsubo Cardiomyopathy 462

 Stressors Reported to Trigger Takotsubo Cardiomyopathy..... 462

 Mayo Clinic Criteria for Takotsubo Cardiomyopathy 464

 References..... 465

30 Acute Coronary Syndromes..... 471

 Unstable Angina/NSTEMI..... 471

 Canadian Cardiovascular Classification of Angina..... 472

 Types of Presentations of Unstable Angina 472

 Differential Diagnosis 472

 Electrocardiography 472

 Tropinins 473

 Management of UA/NSTEMI..... 473

 Risk Stratification..... 473

 Thrombolysis in Myocardial Infarction (TIMI) Risk Score..... 473

 Global Registry of Acute Coronary Events (GRACE) Risk Model 474

 Treatment Approach for UA and NSTEMI (PER AHA Guidelines) 474

 Class I Recommendations..... 474

 Class II Recommendations 475

 Treatment Approach to STEMI (PER AHA Guidelines)..... 475

 Class I Recommendations..... 475

 Class II Recommendations 476

 Complications Following STEMI..... 477

 Recurrent Chest Pain Post-AMI..... 477

 Mitral Regurgitation..... 477

- Left Ventricular Failure and Low Output States 478
- Right Ventricular Infarction 478
- Atrial Fibrillation 478
- References..... 479
- 31 Arrhythmias 481**
- Arrhythmias and Electrolyte Disturbances 481
- Acute Atrial Fibrillation/Flutter 482
- Urgent Cardioversion..... 483
- Rate Control 483
- Pharmacologic Cardioversion 484
- Anticoagulation..... 484
- Multifocal Atrial Tachycardia (MAT) 485
- Paroxysmal Supraventricular Tachycardia (PSVT) 485
- Management..... 486
- SVT Mediated by Accessory Pathways 486
- Sinus Bradycardia 487
- Sick-Sinus Syndrome..... 487
- Accelerated Idioventricular Rhythm..... 487
- Ventricular Premature Complexes and Bigeminy 487
- Nonsustained Ventricular Tachycardia..... 488
- Sustained Ventricular Tachycardia 488
- Polymorphic Ventricular Tachycardia (Torsades De Pointes)..... 489
- Management..... 489
- References..... 490
- Part IV Gastrointestinal**
- 32 Nutrition in the ICU: It’s Whey Cool..... 493**
- Myths of Nutritional Support..... 494
- Important Points to Digest 495
- How Many Calories and How Much Protein to Give? 498
- Muscle Wasting in Critical Illness 499
- Factors That Activate Muscle Synthesis by the mTOR Pathway..... 502
- Bolus vs. Continuous Feeding 504
- So! What is the Best Way to Feed Critically Ill Patients?..... 506
- The Obese Patient 507
- The Refeeding Syndrome 507
- References..... 508
- 33 Stress Ulcer Prophylaxis..... 513**
- Does SUP Reduce GI Bleeding?..... 514
- Enteral Nutrition and Stress-ulcer Prophylaxis..... 515
- Complications Associated with Acid Suppressive Therapy..... 516
- So! What to Do?..... 517
- Complications Associated with Specific Drugs 517

H2 Receptor Antagonists (H2RA)	517
Proton Pump Inhibitors (PPIs).....	518
Sucralfate	518
References.....	519
34 Acute and Chronic Liver Disease	523
Chronic Liver Failure.....	523
Causes of Cirrhosis	524
Metabolic/Hematologic Derangements in Cirrhosis.....	525
Spontaneous Bacterial Peritonitis	525
Hepatic Encephalopathy	527
Grades of Hepatic Encephalopathy.....	528
Hepatorenal Syndrome.....	529
Hepatorenal Syndrome: Diagnostic Criteria.....	530
Diagnostic Approach.....	530
Treatment of HRS	531
Hepato-adrenal Syndrome	532
Pulmonary Consequences of Portal Hypertension.....	532
Infection and Cirrhosis.....	532
Supportive Care of the Hospitalized Cirrhotic.....	533
The Coagulopathy of Chronic Liver Disease.....	534
Portal Vein Thrombosis.....	535
Acute-on-chronic Liver Failure.....	537
Alcoholic Hepatitis	538
Differential Diagnosis	539
Management.....	539
Fulminant Hepatic Failure	540
Causes of Fulminant Hepatic Failure.....	541
Workup of Patients Presenting with FHF	541
Cerebral Edema in FHF	542
Management of Increased ICP.....	543
Supportive Measures	545
Indications for Liver Transplantation.....	545
Kings Criteria.....	546
References.....	546
35 GI Bleeding	551
Initial Assessment	551
Initial Resuscitation	553
Triage of Patients. Who to Admit to the ICU?.....	555
Upper GI Bleeding.....	555
The Major Causes of UGIB Include	556
Further Management of Upper GI Bleeding (See Fig. 35.1).....	556
Further Management of Bleeding Peptic Ulcers.....	557
Recurrent Hemorrhage.....	559

Further Management of Esophageal Varices..... 559

Management of Patients with Lower GI Bleeding..... 560

References..... 562

36 Pancreatitis 565

 Diagnosis..... 566

 Risk Stratification..... 567

 Complications 568

 Management..... 569

 References..... 571

37 Diarrhea & Constipation..... 575

 Diarrhea..... 575

 Infectious Diarrhea..... 575

 “Non-Infectious” Diarrhea..... 576

 Antibiotic Associated Diarrhea (AAD)..... 576

 Enteral Feeding-Associated Diarrhoea 576

 Management of “Non-Infectious” Diarrhoea..... 576

 The Use of Probiotics and Prebiotics..... 577

 Constipation 579

 References..... 580

Part V Miscellaneous

38 Transfusion of Blood and Blood Products 585

 Red Blood Cell Transfusions 585

 Why Transfuse? 586

 Risks Associated with Blood Transfusion (See Fig. 38.1)..... 586

 Risks Associated with Blood Transfusion..... 587

 Transfusion-Associated Immunomodulation..... 588

 “Age” of Transfused Red Blood Cells 590

 Tolerance to Anemia 596

 Weighing the Risks and Benefits of Blood Transfusion 596

 So, When Should Patients’ Be Transfused? 597

 Coagulation Disorders in the ICU..... 598

 Fresh Frozen Plasma 600

 FFP Prior to Invasive Bedside Procedures or Surgery 601

 Paracentesis..... 604

 Management of Non-therapeutic INRs With or Without Bleeding
 (Due to Coumadin Therapy) 604

 Platelet Transfusion..... 606

 Heparin Associated Thrombocytopenia..... 610

 Thrombotic Thrombocytopenic Purpura (TTP)..... 612

 Cryprecipitate..... 614

 References..... 614

39	Adrenal Insufficiency	621
	Causes of Adrenal Insufficient/Circi.....	622
	Clinical Features of Adrenal Insufficiency/Circi.....	623
	Diagnosis of Adrenal Insufficiency/Circi.....	624
	Factors Affecting the Response to Corticosteroid Treatment.....	625
	The Immune Status of the Host.....	625
	Timing of Corticosteroids.....	626
	Dose and Dosing Strategy.....	626
	Acute Rebound After Discontinuation of Corticosteroids.....	627
	Genetic Polymorphisms.....	627
	Abnormalities of the Glucocorticoid Receptor.....	628
	Treatment of Adrenal Insufficiency/CIRCI.....	628
	Who to Treat with Steroids?.....	628
	Adverse Effects of Corticosteroids.....	630
	References.....	631
40	Electrolyte Disturbances	635
	Sodium and Water.....	635
	Rules of the Game.....	635
	Hyponatremia.....	635
	Hypernatremia.....	640
	Hypokalemia.....	641
	Hyperkalemia.....	641
	Hypophosphatemia.....	642
	Management.....	643
	Hypomagnesemia.....	643
	Management of Hypomagnesemia.....	644
	Disorders of Calcium Homeostasis.....	645
	Hypocalcemia.....	646
	Should Hypocalcemia Be Corrected in Critically Ill Patients?.....	647
	Treatment.....	647
	Hypercalcemia.....	648
	Treatment.....	649
	Second Line.....	649
	Additional Therapies.....	650
	References.....	650
41	Acute Kidney Injury	653
	Pre-Renal Azotemia.....	654
	Contrast Agents and the Kidney.....	655
	Prevention of Contrast Induced AKI.....	655
	“Common” Nephrotoxic Agents.....	656
	Management of Established Acute Renal Failure.....	657
	When to Initiate Renal Replacement Therapy (RRT).....	657

Mode of Renal Replacement Therapy	658
Advantages of CRRT Therapy Include	658
Dosing of RRT	659
Summary of Recommendations for RRT in Patients with AKI.....	659
Rhabdomyolysis.....	659
Epidemiology	660
Etiology.....	660
Pathophysiology.....	663
Mechanisms of Acute Renal Failure in Rhabdomyolysis Patients	663
Clinical Manifestations	663
Laboratory Findings.....	664
Management.....	664
Dialysis	665
References.....	666
42 Acute Ischemic Stroke	669
Stroke ICU's, Medical ICU's or Stroke Units.....	670
Profiles Predictive of Futility After Devastating Stroke.....	670
Acute Ischemic Stroke (AIS).....	671
Imaging	671
Thrombolytic Therapy	672
Treatment of Acute Ischemic Stroke With Intravenous rtPA	674
Endovascular Interventions.....	675
Antiplatelet Therapy and Anti-Coagulation.....	676
Anticoagulation in Cardio-Embolic Stroke	676
Raised ICP and Decompressive Surgery.....	677
Treatment of Hyperglycemia	678
Treatment of Fever	678
Treatment of Post Stroke Hypertension	678
Supportive Medical Therapy.....	680
References.....	681
43 Intracerebral and Subarachnoid Hemorrhage	685
Intracerebral Hemorrhage	685
Medical Management.....	687
Blood Pressure Control	689
Surgical Interventions	690
Subarachnoid Hemorrhage.....	692
Diagnosis and Evaluation.....	693
Initial Management	693
Specific Therapeutic Issues.....	698
Antifibrinolytic Therapy	698
Surgical and Endovascular Methods of Treatment	698
Management of Cerebral Vasospasm	698
Transpulmonary Thermodilution (TPTD)	
Hemodynamic Assessment	701

Subdural Hematoma.....	702
Epidural Hematoma	703
Increased Intracranial Pressure (ICP)	703
Measurement of ICP	704
Indications for ICP Monitoring.....	704
Management of Raised ICP	705
References.....	708
44 Seizures & Status Epilepticus	717
Seizures in the ICU	717
Seizures Occurring as a Complication of Critical Illness	718
Seizures from Primary Neurological Disease	719
Management.....	719
Seizure Therapy	719
Status Epilepticus.....	720
Etiology.....	721
Common Causes of Status Epilepticus Include	721
Pathophysiology.....	722
Complications of Generalized Status Epilepticus.....	722
Diagnosis.....	722
Treatment	723
General Measures.....	723
Pharmacotherapy.....	724
Management of Refractory Status Epilepticus	726
The Management of Nonconvulsive Status Epilepticus	727
Prevention of Seizure Recurrence Once Status Epilepticus is Terminated.....	728
References.....	728
45 Toxicology	731
General Measures.....	731
Technique for Performing Gastric Lavage.....	732
Activated Charcoal.....	732
Hemodialysis/Hemoperfusion.....	733
Common Agents Responsible for	734
Common Intoxications.....	735
Acetaminophen	735
Salicylates	738
Tricyclic Antidepressants	738
Acute Ethanol Intoxication	739
Ethylene Glycol and Methanol Poisoning	740
Ethylene Glycol	740
Methanol	741
Isopropyl Alcohol.....	742
Digitalis.....	743
Phenytoin	743
Lithium.....	744

Opiates	745
Cocaine	745
Carbon Monoxide Poisoning	748
References.....	750
46 Alcohol Withdrawal Syndrome	751
The Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar).....	753
Differential Diagnosis.....	753
Treatment	754
Other Treatment Considerations	755
Prevention of Post-operative DT's	756
References.....	756
47 Pregnancy Related Disorders.....	759
Obstetrical Hemorrhage	760
Antepartum Hemorrhage	760
Postpartum Hemorrhage	760
Management.....	760
Hypertension.....	761
Pre-eclampsia.....	761
Diagnosis of Pre-eclampsia.....	762
HELLP Syndrome.....	764
Posterior Reversible Encephalopathy Syndrome (PRES).....	765
Treatment of Pre-eclampsia	765
Anti-hypertensive Agents for the Treatment of Pre-eclampsia.....	766
Corticosteroids and Plasmapheresis as Adjunctive Treatment of HELLP.....	767
Acute Fatty Liver of Pregnancy	768
Amniotic Fluid Embolus Syndrome	768
Sepsis in Pregnancy	768
Respiratory Failure in Pregnancy.....	769
References.....	770
48 The Geriatric ICU Patient.....	773
The Physiology of Aging	773
Cardiovascular Changes.....	774
Changes in Respiratory Function.....	775
Changes in Renal Function	775
Immune System Changes.....	776
Body Composition and Muscle Mass	776
The Outcome of Elderly Patients Admitted to the ICU	776
Trauma and the Elderly Patient.....	778
Surgery and the Elderly.....	778
Delirium in the Elderly	779
Drug Dosing and Polypharmacy in the Elderly	780

American Geriatric Society Beers Criteria	781
Drugs to Avoid in the Elderly	781
References	782
49 Obesity in the ICU	787
Effect of Obesity on Critical Care Outcomes	787
Respiratory Effects of Obesity	788
Ideal Body Weight.....	789
Cardiovascular Effects of Obesity	789
Hepatic and Renal Effects of Obesity	790
Drug Dosing in Obese Patients	790
Nutritional Requirements.....	790
Gaining Vascular Access	791
Radiological Procedures	791
Malignant Obesity Hypoventilation Syndrome (MOHS)	791
Major Criteria.....	792
Minor Criteria	792
Treatment of MOHS	792
References.....	793
50 Radiology	797
The Chest Radiograph.....	797
Position of Tubes and Catheters.....	798
Lung Parenchyma, Pleura and Mediastinum	798
Plain Abdominal Radiography.....	801
Computed Tomography (CT).....	801
Indium Labeled Leukocyte Scans	802
References.....	803
51 End-of-Life Issues	805
Palliative Care	806
“Principles” of Palliative Care	807
References.....	809
52 Words of Wisdom.....	811
References.....	812
Index.....	813



<http://www.springer.com/978-3-319-11019-6>

Evidence-Based Critical Care

Marik, P.E.

2015, XXXIII, 835 p. 83 illus., 46 illus. in color., Softcover

ISBN: 978-3-319-11019-6